Insider filing
Traded Feb 17 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 20, 2026 · Filed Jan 21, 2026
A Gilead Sciences director sold $618K of Gilead Sciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$617,500
Shares × reported transaction price
82 days after results of Oct 30, 2025, 21 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $124.14 on Jan 20, 2026, within 4% of its 52-week high, after a 1% rise over the previous 30 trading days
52-week range $92.92 (Jan 23, 2025) to $128.07 (Nov 19, 2025), 89% of the way up, from 251 adjusted closes. 30 trading days earlier: $122.62 on Dec 4, 2025. Describes the past only, not a forecast
RSI 53, 8% above its 200-day average, at its 50-day average, 3% below the 52-week high, 20-day volatility 28% a year, against the S&P 500: +1 points over 1 month, −1 points over 3 months, +7 points over 6 months
From the adjusted closes up to Jan 20, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
A WARN layoff notice covering 34 workers was filed in California on January 21, 2026.
From the official state WARN list, 1 day after the trade. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +6.4% | +0.7% | +5.7% |
| 30 days | +14.3% | −1.0% | +15.2% |
| 90 days | +1.3% | +3.2% | −1.9% |
| 180 days | −0.7% | +8.6% | −9.3% |
Past results only. Not a forecast.
Insider filing
Traded Feb 17 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$2.84M of Gilead Sciences
Planned saleJohanna Mercier (Chief Comm & Corp Aff Officer) sold ~$1.46M of Gilead Sciences
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.